| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Echocardiography, Three-Dimensional | 196 | 2024 | 516 | 37.780 |
Why?
|
| Echocardiography | 251 | 2023 | 937 | 25.880 |
Why?
|
| Heart Ventricles | 145 | 2024 | 779 | 17.960 |
Why?
|
| Ventricular Function, Left | 148 | 2023 | 603 | 16.760 |
Why?
|
| Ventricular Dysfunction, Left | 87 | 2023 | 329 | 16.140 |
Why?
|
| Echocardiography, Transesophageal | 98 | 2023 | 346 | 13.990 |
Why?
|
| Mitral Valve | 54 | 2022 | 262 | 11.200 |
Why?
|
| Stroke Volume | 104 | 2024 | 462 | 11.120 |
Why?
|
| Tricuspid Valve Insufficiency | 23 | 2023 | 113 | 9.330 |
Why?
|
| Image Interpretation, Computer-Assisted | 71 | 2020 | 685 | 9.010 |
Why?
|
| Mitral Valve Insufficiency | 34 | 2022 | 192 | 7.760 |
Why?
|
| Echocardiography, Doppler | 58 | 2023 | 186 | 7.280 |
Why?
|
| Reproducibility of Results | 140 | 2023 | 2752 | 5.970 |
Why?
|
| Heart Diseases | 38 | 2021 | 298 | 5.790 |
Why?
|
| Heart Atria | 39 | 2023 | 281 | 5.660 |
Why?
|
| Ventricular Dysfunction, Right | 18 | 2024 | 136 | 5.590 |
Why?
|
| Image Enhancement | 53 | 2017 | 567 | 5.580 |
Why?
|
| Echocardiography, Doppler, Color | 32 | 2022 | 103 | 5.390 |
Why?
|
| Aortic Valve Stenosis | 21 | 2023 | 143 | 5.350 |
Why?
|
| Heart Failure | 48 | 2023 | 1180 | 5.320 |
Why?
|
| Myocardial Contraction | 47 | 2021 | 252 | 4.930 |
Why?
|
| Ventricular Function, Right | 22 | 2024 | 146 | 4.830 |
Why?
|
| Tricuspid Valve | 19 | 2023 | 97 | 4.760 |
Why?
|
| Humans | 584 | 2024 | 89063 | 4.690 |
Why?
|
| Aortic Valve | 25 | 2023 | 243 | 4.660 |
Why?
|
| Heart | 36 | 2023 | 573 | 4.290 |
Why?
|
| Male | 372 | 2024 | 42251 | 4.150 |
Why?
|
| Amyloidosis | 10 | 2023 | 127 | 4.140 |
Why?
|
| Hemodynamics | 50 | 2020 | 729 | 4.090 |
Why?
|
| Middle Aged | 307 | 2023 | 25863 | 4.010 |
Why?
|
| Predictive Value of Tests | 76 | 2023 | 1715 | 3.950 |
Why?
|
| Female | 367 | 2024 | 46011 | 3.860 |
Why?
|
| Cardiomyopathies | 20 | 2023 | 264 | 3.850 |
Why?
|
| Atrial Function, Left | 15 | 2021 | 50 | 3.630 |
Why?
|
| Sensitivity and Specificity | 88 | 2020 | 2014 | 3.580 |
Why?
|
| Contrast Media | 57 | 2023 | 1090 | 3.580 |
Why?
|
| Magnetic Resonance Imaging, Cine | 27 | 2023 | 161 | 3.510 |
Why?
|
| Myocardial Ischemia | 23 | 2020 | 161 | 3.410 |
Why?
|
| Algorithms | 40 | 2021 | 1875 | 3.370 |
Why?
|
| Aged | 196 | 2024 | 19077 | 3.290 |
Why?
|
| Heart-Assist Devices | 21 | 2021 | 756 | 3.200 |
Why?
|
| Diastole | 43 | 2023 | 141 | 2.930 |
Why?
|
| Pacemaker, Artificial | 7 | 2022 | 94 | 2.880 |
Why?
|
| Heart Valve Diseases | 18 | 2017 | 115 | 2.810 |
Why?
|
| Adult | 201 | 2024 | 26507 | 2.780 |
Why?
|
| Image Processing, Computer-Assisted | 40 | 2019 | 1239 | 2.760 |
Why?
|
| Ventricular Remodeling | 15 | 2022 | 105 | 2.500 |
Why?
|
| Defibrillators, Implantable | 6 | 2022 | 142 | 2.490 |
Why?
|
| Observer Variation | 48 | 2023 | 610 | 2.470 |
Why?
|
| Prospective Studies | 68 | 2023 | 4273 | 2.470 |
Why?
|
| Endocardium | 24 | 2020 | 98 | 2.450 |
Why?
|
| Magnetic Resonance Imaging | 44 | 2023 | 3443 | 2.350 |
Why?
|
| Severity of Illness Index | 46 | 2023 | 1837 | 2.340 |
Why?
|
| Feasibility Studies | 52 | 2022 | 779 | 2.330 |
Why?
|
| Hypertrophy, Left Ventricular | 17 | 2022 | 70 | 2.210 |
Why?
|
| Electrocardiography | 25 | 2019 | 493 | 2.210 |
Why?
|
| Cardiology | 13 | 2023 | 115 | 2.190 |
Why?
|
| Heart Valve Prosthesis | 12 | 2021 | 97 | 2.180 |
Why?
|
| Fluorocarbons | 19 | 2019 | 72 | 2.140 |
Why?
|
| Cardiovascular Diseases | 17 | 2021 | 705 | 2.130 |
Why?
|
| Reference Values | 50 | 2023 | 661 | 2.090 |
Why?
|
| Cardiac Volume | 11 | 2017 | 53 | 2.040 |
Why?
|
| Cardiomyopathy, Dilated | 22 | 2012 | 101 | 2.010 |
Why?
|
| Cardiac Catheterization | 33 | 2021 | 302 | 1.980 |
Why?
|
| Heart Valve Prosthesis Implantation | 12 | 2021 | 178 | 1.960 |
Why?
|
| Hypertension, Pulmonary | 12 | 2016 | 352 | 1.950 |
Why?
|
| Myocardial Infarction | 15 | 2020 | 373 | 1.880 |
Why?
|
| Practice Guidelines as Topic | 20 | 2017 | 1043 | 1.870 |
Why?
|
| Echocardiography, Doppler, Pulsed | 10 | 2019 | 23 | 1.840 |
Why?
|
| Aged, 80 and over | 57 | 2023 | 6777 | 1.820 |
Why?
|
| Machine Learning | 7 | 2020 | 257 | 1.780 |
Why?
|
| Dobutamine | 23 | 2013 | 61 | 1.770 |
Why?
|
| Models, Cardiovascular | 15 | 2016 | 106 | 1.770 |
Why?
|
| Aortic Valve Insufficiency | 16 | 2023 | 132 | 1.730 |
Why?
|
| Atrial Fibrillation | 9 | 2023 | 350 | 1.720 |
Why?
|
| Transillumination | 3 | 2021 | 9 | 1.680 |
Why?
|
| Aortic Diseases | 7 | 2019 | 100 | 1.670 |
Why?
|
| Pulmonary Embolism | 7 | 2023 | 228 | 1.620 |
Why?
|
| Exercise Test | 17 | 2015 | 165 | 1.610 |
Why?
|
| Computer Systems | 14 | 2014 | 79 | 1.580 |
Why?
|
| Systole | 31 | 2020 | 115 | 1.570 |
Why?
|
| Chordae Tendineae | 3 | 2015 | 23 | 1.540 |
Why?
|
| Aorta, Thoracic | 8 | 2019 | 166 | 1.530 |
Why?
|
| Coronary Circulation | 22 | 2015 | 131 | 1.530 |
Why?
|
| Retrospective Studies | 51 | 2023 | 9003 | 1.510 |
Why?
|
| Societies, Medical | 15 | 2019 | 570 | 1.500 |
Why?
|
| Myocardium | 23 | 2022 | 571 | 1.500 |
Why?
|
| Aorta | 15 | 2021 | 288 | 1.490 |
Why?
|
| Imaging, Three-Dimensional | 20 | 2020 | 595 | 1.460 |
Why?
|
| Aging | 13 | 2024 | 716 | 1.450 |
Why?
|
| Prognosis | 42 | 2021 | 3773 | 1.400 |
Why?
|
| Anemia, Sickle Cell | 7 | 2017 | 144 | 1.370 |
Why?
|
| Ventricular Function | 10 | 2008 | 53 | 1.360 |
Why?
|
| Cardiac Surgical Procedures | 12 | 2021 | 475 | 1.340 |
Why?
|
| Vasodilator Agents | 16 | 2019 | 146 | 1.340 |
Why?
|
| Mitral Valve Prolapse | 6 | 2020 | 24 | 1.250 |
Why?
|
| Software | 18 | 2022 | 665 | 1.250 |
Why?
|
| Ultrasonography | 18 | 2020 | 711 | 1.190 |
Why?
|
| Echocardiography, Stress | 6 | 2010 | 20 | 1.190 |
Why?
|
| Point-of-Care Systems | 5 | 2021 | 148 | 1.140 |
Why?
|
| Heart Neoplasms | 5 | 2005 | 63 | 1.140 |
Why?
|
| Heart Septal Defects, Atrial | 9 | 2015 | 67 | 1.110 |
Why?
|
| Elasticity Imaging Techniques | 8 | 2016 | 56 | 1.110 |
Why?
|
| Myocardial Perfusion Imaging | 10 | 2019 | 47 | 1.090 |
Why?
|
| Pandemics | 3 | 2021 | 771 | 1.090 |
Why?
|
| Coronary Angiography | 16 | 2019 | 242 | 1.080 |
Why?
|
| Cardiac Pacing, Artificial | 6 | 2010 | 98 | 1.070 |
Why?
|
| Blood Pressure | 21 | 2023 | 899 | 1.050 |
Why?
|
| Stroke | 6 | 2017 | 982 | 1.040 |
Why?
|
| Albumins | 9 | 2019 | 129 | 1.000 |
Why?
|
| Transcatheter Aortic Valve Replacement | 2 | 2017 | 51 | 1.000 |
Why?
|
| Mitral Valve Stenosis | 11 | 2011 | 38 | 0.970 |
Why?
|
| Thrombosis | 7 | 2023 | 302 | 0.950 |
Why?
|
| Coronary Artery Disease | 11 | 2019 | 362 | 0.950 |
Why?
|
| Risk Assessment | 19 | 2019 | 2290 | 0.950 |
Why?
|
| Sarcoidosis | 6 | 2020 | 72 | 0.950 |
Why?
|
| Patient Selection | 9 | 2019 | 682 | 0.940 |
Why?
|
| Heart Valves | 3 | 2017 | 24 | 0.940 |
Why?
|
| Atrial Appendage | 5 | 2021 | 31 | 0.930 |
Why?
|
| Pericardial Effusion | 1 | 2023 | 20 | 0.920 |
Why?
|
| Atrial Function, Right | 4 | 2020 | 13 | 0.900 |
Why?
|
| Risk Factors | 28 | 2023 | 5466 | 0.890 |
Why?
|
| Hypertension | 12 | 2010 | 741 | 0.880 |
Why?
|
| Arrhythmogenic Right Ventricular Dysplasia | 1 | 2023 | 10 | 0.880 |
Why?
|
| Coronary Vessels | 10 | 2018 | 190 | 0.880 |
Why?
|
| Blood Flow Velocity | 14 | 2023 | 198 | 0.870 |
Why?
|
| Cardiovascular System | 8 | 2023 | 62 | 0.850 |
Why?
|
| Guideline Adherence | 6 | 2011 | 229 | 0.840 |
Why?
|
| Takotsubo Cardiomyopathy | 1 | 2022 | 11 | 0.820 |
Why?
|
| Case-Control Studies | 23 | 2019 | 1855 | 0.810 |
Why?
|
| Immunoglobulin Light-chain Amyloidosis | 1 | 2022 | 22 | 0.810 |
Why?
|
| Coronary Stenosis | 8 | 2019 | 39 | 0.800 |
Why?
|
| Tomography, X-Ray Computed | 23 | 2020 | 2657 | 0.800 |
Why?
|
| United States | 33 | 2021 | 6955 | 0.800 |
Why?
|
| Aortic Rupture | 6 | 2003 | 57 | 0.780 |
Why?
|
| Artifacts | 7 | 2021 | 245 | 0.780 |
Why?
|
| Diagnostic Imaging | 4 | 2014 | 479 | 0.770 |
Why?
|
| Cardiac Imaging Techniques | 3 | 2020 | 25 | 0.770 |
Why?
|
| Young Adult | 30 | 2022 | 6288 | 0.770 |
Why?
|
| Time Factors | 32 | 2021 | 5320 | 0.750 |
Why?
|
| Calcinosis | 3 | 2012 | 230 | 0.740 |
Why?
|
| Diagnosis, Differential | 16 | 2019 | 1591 | 0.740 |
Why?
|
| Ventricular Pressure | 7 | 2023 | 37 | 0.730 |
Why?
|
| Europe | 13 | 2021 | 321 | 0.730 |
Why?
|
| Follow-Up Studies | 26 | 2021 | 3657 | 0.720 |
Why?
|
| Ventricular Dysfunction | 4 | 2015 | 28 | 0.700 |
Why?
|
| Vascular Stiffness | 2 | 2019 | 29 | 0.700 |
Why?
|
| Guidelines as Topic | 2 | 2019 | 160 | 0.680 |
Why?
|
| Movement | 5 | 2006 | 307 | 0.680 |
Why?
|
| Organ Size | 11 | 2019 | 369 | 0.680 |
Why?
|
| Signal Processing, Computer-Assisted | 6 | 2003 | 202 | 0.680 |
Why?
|
| Multidetector Computed Tomography | 3 | 2020 | 59 | 0.670 |
Why?
|
| Age Factors | 19 | 2018 | 1867 | 0.670 |
Why?
|
| Treatment Outcome | 34 | 2023 | 8203 | 0.670 |
Why?
|
| Carotid Arteries | 2 | 2011 | 127 | 0.660 |
Why?
|
| Coronary Disease | 9 | 2010 | 260 | 0.660 |
Why?
|
| Gadolinium DTPA | 6 | 2020 | 264 | 0.640 |
Why?
|
| Pattern Recognition, Automated | 6 | 2016 | 217 | 0.630 |
Why?
|
| Cardiac Output | 9 | 2021 | 156 | 0.620 |
Why?
|
| Heart Septal Defects, Ventricular | 4 | 2019 | 69 | 0.620 |
Why?
|
| Linear Models | 19 | 2020 | 421 | 0.620 |
Why?
|
| Vascular Calcification | 1 | 2019 | 51 | 0.620 |
Why?
|
| Adolescent | 30 | 2022 | 9237 | 0.620 |
Why?
|
| Automation | 9 | 2019 | 111 | 0.600 |
Why?
|
| Cor Triatriatum | 3 | 2006 | 3 | 0.600 |
Why?
|
| Antihypertensive Agents | 4 | 2013 | 249 | 0.590 |
Why?
|
| Peripheral Vascular Diseases | 3 | 2006 | 61 | 0.590 |
Why?
|
| Anticoagulants | 3 | 2018 | 426 | 0.590 |
Why?
|
| Pre-Eclampsia | 5 | 2021 | 254 | 0.580 |
Why?
|
| Septal Occluder Device | 8 | 2020 | 44 | 0.570 |
Why?
|
| Chicago | 15 | 2019 | 1423 | 0.570 |
Why?
|
| Forecasting | 8 | 2018 | 305 | 0.570 |
Why?
|
| Betacoronavirus | 1 | 2020 | 261 | 0.560 |
Why?
|
| Practice Patterns, Physicians' | 8 | 2011 | 599 | 0.560 |
Why?
|
| Embolism | 2 | 2008 | 32 | 0.560 |
Why?
|
| Atherosclerosis | 2 | 2018 | 255 | 0.560 |
Why?
|
| Holography | 1 | 2016 | 5 | 0.550 |
Why?
|
| Torsion Abnormality | 4 | 2009 | 17 | 0.550 |
Why?
|
| Healthy Volunteers | 9 | 2022 | 145 | 0.550 |
Why?
|
| Electrodes, Implanted | 2 | 2014 | 177 | 0.550 |
Why?
|
| Ischemic Attack, Transient | 3 | 2008 | 182 | 0.550 |
Why?
|
| Cohort Studies | 19 | 2020 | 2863 | 0.540 |
Why?
|
| Workflow | 3 | 2023 | 80 | 0.530 |
Why?
|
| Sex Factors | 14 | 2020 | 1063 | 0.520 |
Why?
|
| Artificial Intelligence | 8 | 2023 | 322 | 0.520 |
Why?
|
| Iatrogenic Disease | 2 | 2013 | 70 | 0.520 |
Why?
|
| Anatomic Landmarks | 1 | 2015 | 30 | 0.520 |
Why?
|
| Heart Rate | 13 | 2012 | 493 | 0.510 |
Why?
|
| Preoperative Care | 5 | 2018 | 396 | 0.510 |
Why?
|
| ROC Curve | 10 | 2020 | 781 | 0.500 |
Why?
|
| Quality Improvement | 2 | 2016 | 447 | 0.500 |
Why?
|
| Purines | 6 | 2016 | 93 | 0.500 |
Why?
|
| Prevalence | 12 | 2022 | 1240 | 0.500 |
Why?
|
| Aneurysm, False | 3 | 2004 | 54 | 0.490 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 319 | 0.490 |
Why?
|
| Diagnostic Techniques, Cardiovascular | 2 | 2011 | 12 | 0.490 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 304 | 0.490 |
Why?
|
| Heart Septum | 3 | 2011 | 47 | 0.490 |
Why?
|
| Bioprosthesis | 3 | 2021 | 39 | 0.480 |
Why?
|
| Atrial Function | 2 | 2007 | 19 | 0.480 |
Why?
|
| Pregnancy Complications, Cardiovascular | 4 | 2005 | 109 | 0.480 |
Why?
|
| Pyrazoles | 6 | 2016 | 150 | 0.470 |
Why?
|
| Monitoring, Intraoperative | 2 | 2018 | 110 | 0.470 |
Why?
|
| Veins | 1 | 2014 | 95 | 0.470 |
Why?
|
| Myxoma | 2 | 2004 | 30 | 0.460 |
Why?
|
| Terminology as Topic | 3 | 2019 | 221 | 0.460 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 8 | 2016 | 94 | 0.460 |
Why?
|
| Education, Medical, Continuing | 4 | 2019 | 105 | 0.460 |
Why?
|
| Fibroma | 2 | 2005 | 33 | 0.460 |
Why?
|
| Prosthesis Design | 8 | 2021 | 296 | 0.460 |
Why?
|
| Heart Block | 1 | 2013 | 31 | 0.450 |
Why?
|
| Pulmonary Artery | 6 | 2019 | 319 | 0.440 |
Why?
|
| Equipment Design | 8 | 2016 | 415 | 0.440 |
Why?
|
| Prosthesis Failure | 3 | 2016 | 116 | 0.440 |
Why?
|
| Electrodes | 1 | 2013 | 88 | 0.440 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 3 | 1997 | 91 | 0.430 |
Why?
|
| Catheterization | 9 | 2013 | 237 | 0.430 |
Why?
|
| Intraoperative Care | 1 | 2013 | 84 | 0.430 |
Why?
|
| Physical Examination | 5 | 2020 | 148 | 0.420 |
Why?
|
| Anemia, Hemolytic | 2 | 2004 | 19 | 0.420 |
Why?
|
| Balloon Occlusion | 5 | 2012 | 29 | 0.420 |
Why?
|
| Tachycardia, Ventricular | 4 | 2023 | 124 | 0.410 |
Why?
|
| Manometry | 3 | 2011 | 44 | 0.410 |
Why?
|
| Cardiomyopathy, Hypertrophic | 3 | 2003 | 42 | 0.410 |
Why?
|
| Data Display | 1 | 2012 | 24 | 0.400 |
Why?
|
| Clinical Competence | 6 | 2019 | 780 | 0.400 |
Why?
|
| Papillary Muscles | 3 | 2008 | 17 | 0.400 |
Why?
|
| Child, Preschool | 11 | 2013 | 3717 | 0.400 |
Why?
|
| Coronary Artery Bypass | 5 | 2017 | 234 | 0.390 |
Why?
|
| Magnetic Resonance Spectroscopy | 4 | 2023 | 312 | 0.390 |
Why?
|
| American Heart Association | 3 | 2020 | 94 | 0.380 |
Why?
|
| Models, Statistical | 2 | 2016 | 575 | 0.370 |
Why?
|
| Puerperal Disorders | 3 | 2005 | 32 | 0.370 |
Why?
|
| Heart Defects, Congenital | 7 | 2013 | 363 | 0.370 |
Why?
|
| Syncope | 3 | 2021 | 34 | 0.370 |
Why?
|
| Stress, Mechanical | 6 | 2016 | 253 | 0.370 |
Why?
|
| Italy | 3 | 2019 | 107 | 0.370 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2011 | 172 | 0.360 |
Why?
|
| Atrial Remodeling | 2 | 2022 | 24 | 0.360 |
Why?
|
| Child | 16 | 2018 | 7149 | 0.360 |
Why?
|
| Cardiotonic Agents | 8 | 2011 | 89 | 0.360 |
Why?
|
| Insurance Carriers | 1 | 2010 | 6 | 0.350 |
Why?
|
| Private Sector | 1 | 2010 | 19 | 0.350 |
Why?
|
| Multivariate Analysis | 10 | 2018 | 988 | 0.350 |
Why?
|
| Internal Medicine | 3 | 1998 | 355 | 0.350 |
Why?
|
| Decision Making | 2 | 2018 | 665 | 0.340 |
Why?
|
| Cardiac Output, Low | 2 | 2007 | 14 | 0.340 |
Why?
|
| Radiology | 4 | 2016 | 199 | 0.340 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2010 | 60 | 0.340 |
Why?
|
| Cardiac Resynchronization Therapy | 2 | 2021 | 68 | 0.340 |
Why?
|
| Surgical Wound Dehiscence | 1 | 2009 | 37 | 0.330 |
Why?
|
| Adrenergic beta-Agonists | 6 | 2002 | 72 | 0.330 |
Why?
|
| Bundle-Branch Block | 1 | 2009 | 54 | 0.320 |
Why?
|
| Cannula | 3 | 2019 | 50 | 0.320 |
Why?
|
| Body Surface Area | 1 | 2008 | 36 | 0.320 |
Why?
|
| Transducers | 6 | 2008 | 42 | 0.320 |
Why?
|
| Postpartum Period | 2 | 2021 | 144 | 0.320 |
Why?
|
| Heart Transplantation | 3 | 2018 | 716 | 0.320 |
Why?
|
| Animals | 45 | 2016 | 27317 | 0.320 |
Why?
|
| Anaphylaxis | 1 | 2008 | 33 | 0.320 |
Why?
|
| Sinus of Valsalva | 3 | 2003 | 18 | 0.310 |
Why?
|
| Dilatation, Pathologic | 3 | 2019 | 55 | 0.310 |
Why?
|
| Color | 7 | 2013 | 85 | 0.310 |
Why?
|
| Pregnancy | 12 | 2021 | 3009 | 0.310 |
Why?
|
| Inpatients | 2 | 2021 | 310 | 0.310 |
Why?
|
| Microspheres | 8 | 2013 | 108 | 0.300 |
Why?
|
| Tomography, Spiral Computed | 1 | 2008 | 77 | 0.300 |
Why?
|
| Thrombolytic Therapy | 3 | 2016 | 232 | 0.300 |
Why?
|
| Phenotype | 5 | 2022 | 2439 | 0.300 |
Why?
|
| Drug Utilization Review | 2 | 1997 | 14 | 0.300 |
Why?
|
| Disease Models, Animal | 11 | 2011 | 2362 | 0.300 |
Why?
|
| Societies, Scientific | 1 | 2007 | 43 | 0.290 |
Why?
|
| Mitral Valve Annuloplasty | 2 | 2021 | 16 | 0.290 |
Why?
|
| Heart Septal Defects | 3 | 2016 | 32 | 0.290 |
Why?
|
| Perfusion Imaging | 3 | 2015 | 50 | 0.290 |
Why?
|
| Computer Simulation | 5 | 2016 | 1097 | 0.290 |
Why?
|
| Thermodilution | 1 | 2007 | 21 | 0.290 |
Why?
|
| Vasodilation | 2 | 2019 | 93 | 0.280 |
Why?
|
| Swine | 10 | 2016 | 581 | 0.280 |
Why?
|
| Hernia, Hiatal | 1 | 2007 | 38 | 0.280 |
Why?
|
| Coronary Aneurysm | 1 | 2006 | 16 | 0.280 |
Why?
|
| Dipyridamole | 2 | 2005 | 14 | 0.280 |
Why?
|
| Computed Tomography Angiography | 2 | 2019 | 146 | 0.280 |
Why?
|
| Heart Aneurysm | 2 | 2004 | 22 | 0.270 |
Why?
|
| In Vitro Techniques | 8 | 2009 | 996 | 0.270 |
Why?
|
| Enalapril | 2 | 1997 | 13 | 0.270 |
Why?
|
| Ultrasonography, Doppler | 5 | 2023 | 85 | 0.270 |
Why?
|
| Aortic Stenosis, Subvalvular | 1 | 2005 | 5 | 0.270 |
Why?
|
| Aortic Aneurysm | 2 | 2003 | 80 | 0.270 |
Why?
|
| Survival Rate | 6 | 2021 | 1889 | 0.270 |
Why?
|
| Rheumatic Heart Disease | 4 | 2006 | 30 | 0.270 |
Why?
|
| Heart Function Tests | 4 | 2019 | 33 | 0.260 |
Why?
|
| Hypertension, Pregnancy-Induced | 2 | 2018 | 75 | 0.260 |
Why?
|
| Analysis of Variance | 7 | 2016 | 901 | 0.260 |
Why?
|
| Esophageal Perforation | 1 | 2005 | 18 | 0.260 |
Why?
|
| Utilization Review | 2 | 2020 | 23 | 0.260 |
Why?
|
| Recovery of Function | 3 | 2020 | 292 | 0.250 |
Why?
|
| Arteries | 4 | 2005 | 180 | 0.250 |
Why?
|
| Wounds, Stab | 1 | 2005 | 10 | 0.250 |
Why?
|
| Quality of Health Care | 1 | 2008 | 385 | 0.250 |
Why?
|
| Pericardium | 1 | 2005 | 70 | 0.250 |
Why?
|
| Disease Progression | 8 | 2019 | 1488 | 0.250 |
Why?
|
| Angina Pectoris | 2 | 2002 | 28 | 0.250 |
Why?
|
| Heart Arrest | 2 | 2018 | 279 | 0.240 |
Why?
|
| Evaluation Studies as Topic | 5 | 2019 | 270 | 0.240 |
Why?
|
| Arteriosclerosis | 1 | 2004 | 112 | 0.240 |
Why?
|
| Endocarditis, Bacterial | 1 | 2004 | 38 | 0.240 |
Why?
|
| Gadolinium | 2 | 2023 | 103 | 0.240 |
Why?
|
| Statistics as Topic | 4 | 2011 | 234 | 0.240 |
Why?
|
| Streptococcal Infections | 1 | 2004 | 56 | 0.240 |
Why?
|
| Exercise Tolerance | 2 | 2009 | 53 | 0.230 |
Why?
|
| Biopsy | 4 | 2021 | 1182 | 0.230 |
Why?
|
| Cross-Sectional Studies | 6 | 2020 | 1706 | 0.230 |
Why?
|
| Aminobutyrates | 2 | 2023 | 13 | 0.230 |
Why?
|
| Continuous Positive Airway Pressure | 2 | 2017 | 52 | 0.230 |
Why?
|
| Brain Ischemia | 1 | 2008 | 399 | 0.230 |
Why?
|
| Tetrazoles | 2 | 2023 | 24 | 0.230 |
Why?
|
| Plaque, Atherosclerotic | 2 | 2015 | 59 | 0.230 |
Why?
|
| Ischemia | 1 | 2005 | 251 | 0.230 |
Why?
|
| Thrombophilia | 1 | 2023 | 23 | 0.230 |
Why?
|
| Elastic Modulus | 5 | 2016 | 36 | 0.230 |
Why?
|
| Motion | 4 | 2010 | 93 | 0.220 |
Why?
|
| Pulse | 2 | 1994 | 17 | 0.220 |
Why?
|
| Shock, Cardiogenic | 3 | 2013 | 106 | 0.220 |
Why?
|
| Ultrasonography, Interventional | 7 | 2013 | 123 | 0.220 |
Why?
|
| Pleural Neoplasms | 1 | 2005 | 198 | 0.220 |
Why?
|
| Education, Medical, Undergraduate | 2 | 2005 | 178 | 0.220 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2021 | 889 | 0.220 |
Why?
|
| Aneurysm, Infected | 1 | 2003 | 12 | 0.220 |
Why?
|
| Hemoptysis | 1 | 2003 | 24 | 0.220 |
Why?
|
| Vascular Resistance | 6 | 2013 | 101 | 0.220 |
Why?
|
| Stress, Physiological | 3 | 2015 | 229 | 0.220 |
Why?
|
| Aortic Aneurysm, Thoracic | 1 | 2004 | 89 | 0.220 |
Why?
|
| Postoperative Complications | 4 | 2016 | 2275 | 0.210 |
Why?
|
| Illinois | 5 | 2008 | 472 | 0.210 |
Why?
|
| Biomarkers | 8 | 2021 | 1755 | 0.210 |
Why?
|
| Electronics | 1 | 2022 | 17 | 0.210 |
Why?
|
| Regression Analysis | 4 | 2016 | 590 | 0.210 |
Why?
|
| Comorbidity | 4 | 2021 | 948 | 0.210 |
Why?
|
| Biomechanical Phenomena | 6 | 2019 | 473 | 0.210 |
Why?
|
| Angiotensin Receptor Antagonists | 2 | 2023 | 39 | 0.200 |
Why?
|
| Ventricular Fibrillation | 2 | 2023 | 68 | 0.200 |
Why?
|
| Advisory Committees | 2 | 2019 | 88 | 0.200 |
Why?
|
| Streptokinase | 1 | 2001 | 12 | 0.200 |
Why?
|
| Activins | 2 | 2021 | 26 | 0.200 |
Why?
|
| Mesothelioma | 1 | 2005 | 323 | 0.200 |
Why?
|
| Hyperemia | 4 | 2012 | 19 | 0.200 |
Why?
|
| Cardiac-Gated Imaging Techniques | 2 | 2012 | 20 | 0.200 |
Why?
|
| Consensus | 3 | 2019 | 356 | 0.200 |
Why?
|
| Receptors, Thyroid Hormone | 1 | 2002 | 160 | 0.200 |
Why?
|
| Embolization, Therapeutic | 1 | 2005 | 262 | 0.200 |
Why?
|
| Dopamine | 4 | 1992 | 276 | 0.200 |
Why?
|
| Positron-Emission Tomography | 2 | 2020 | 336 | 0.200 |
Why?
|
| Acoustics | 5 | 2003 | 51 | 0.200 |
Why?
|
| Multimodal Imaging | 5 | 2020 | 111 | 0.200 |
Why?
|
| Treatment Failure | 3 | 2009 | 287 | 0.200 |
Why?
|
| Genome-Wide Association Study | 4 | 2019 | 1670 | 0.190 |
Why?
|
| Radionuclide Imaging | 3 | 2016 | 221 | 0.190 |
Why?
|
| Subtraction Technique | 3 | 2016 | 132 | 0.190 |
Why?
|
| Surgery, Computer-Assisted | 2 | 2016 | 98 | 0.190 |
Why?
|
| Cause of Death | 3 | 2017 | 266 | 0.190 |
Why?
|
| Nursing Staff, Hospital | 1 | 2021 | 42 | 0.190 |
Why?
|
| Myocardial Stunning | 2 | 2006 | 12 | 0.190 |
Why?
|
| Chest Pain | 2 | 2018 | 42 | 0.190 |
Why?
|
| Thyroid Hormones | 2 | 2003 | 328 | 0.190 |
Why?
|
| Microbubbles | 2 | 2013 | 36 | 0.180 |
Why?
|
| Diagnostic Errors | 2 | 2014 | 160 | 0.180 |
Why?
|
| Academic Medical Centers | 4 | 2009 | 385 | 0.180 |
Why?
|
| Cardiovascular Physiological Phenomena | 2 | 1997 | 36 | 0.180 |
Why?
|
| Radiopharmaceuticals | 2 | 2020 | 193 | 0.180 |
Why?
|
| Mice, Transgenic | 8 | 2003 | 1574 | 0.180 |
Why?
|
| Heart Murmurs | 1 | 2020 | 6 | 0.180 |
Why?
|
| Infant | 6 | 2018 | 3147 | 0.180 |
Why?
|
| Virtual Reality | 1 | 2020 | 24 | 0.180 |
Why?
|
| Elasticity | 5 | 2011 | 96 | 0.180 |
Why?
|
| Monitoring, Physiologic | 4 | 2015 | 266 | 0.180 |
Why?
|
| Embolism, Air | 2 | 1991 | 23 | 0.180 |
Why?
|
| Random Allocation | 1 | 2020 | 328 | 0.180 |
Why?
|
| Appointments and Schedules | 1 | 2020 | 54 | 0.180 |
Why?
|
| Fibrosis | 1 | 2021 | 234 | 0.170 |
Why?
|
| Rest | 3 | 2016 | 49 | 0.170 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2020 | 142 | 0.170 |
Why?
|
| Fibrinolytic Agents | 1 | 2001 | 214 | 0.170 |
Why?
|
| Cicatrix | 1 | 2020 | 68 | 0.170 |
Why?
|
| Fractional Flow Reserve, Myocardial | 1 | 2019 | 4 | 0.170 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2019 | 46 | 0.170 |
Why?
|
| Protease Inhibitors | 1 | 2019 | 73 | 0.170 |
Why?
|
| Arterial Pressure | 1 | 2019 | 38 | 0.170 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 3 | 2019 | 469 | 0.170 |
Why?
|
| Unnecessary Procedures | 2 | 2010 | 51 | 0.170 |
Why?
|
| Mice | 15 | 2016 | 11737 | 0.160 |
Why?
|
| Magnetic Field Therapy | 1 | 2018 | 1 | 0.160 |
Why?
|
| Societies | 1 | 2018 | 14 | 0.160 |
Why?
|
| Nuclear Family | 1 | 2019 | 92 | 0.160 |
Why?
|
| Documentation | 2 | 2014 | 103 | 0.160 |
Why?
|
| Blood Volume | 2 | 2005 | 49 | 0.160 |
Why?
|
| Diuretics | 1 | 2019 | 75 | 0.160 |
Why?
|
| Ventricular Outflow Obstruction | 2 | 1996 | 21 | 0.160 |
Why?
|
| Bundle of His | 1 | 2019 | 45 | 0.160 |
Why?
|
| Hospitals | 1 | 2021 | 299 | 0.160 |
Why?
|
| Cardiac Resynchronization Therapy Devices | 2 | 2019 | 19 | 0.160 |
Why?
|
| Regional Blood Flow | 3 | 2016 | 198 | 0.160 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 4 | 2011 | 68 | 0.160 |
Why?
|
| Equipment Failure Analysis | 2 | 2008 | 89 | 0.160 |
Why?
|
| Proportional Hazards Models | 5 | 2016 | 848 | 0.160 |
Why?
|
| Diffusion of Innovation | 1 | 2018 | 71 | 0.160 |
Why?
|
| Hemothorax | 1 | 2018 | 15 | 0.160 |
Why?
|
| Heart Massage | 1 | 2018 | 12 | 0.150 |
Why?
|
| Obesity Hypoventilation Syndrome | 1 | 2017 | 2 | 0.150 |
Why?
|
| Chi-Square Distribution | 4 | 2012 | 360 | 0.150 |
Why?
|
| Malignant Carcinoid Syndrome | 1 | 1997 | 4 | 0.150 |
Why?
|
| Losartan | 1 | 1997 | 30 | 0.150 |
Why?
|
| Pulmonary Wedge Pressure | 5 | 2019 | 113 | 0.150 |
Why?
|
| Geriatrics | 1 | 1998 | 66 | 0.150 |
Why?
|
| Intraoperative Period | 3 | 2013 | 90 | 0.150 |
Why?
|
| Vasomotor System | 1 | 1997 | 13 | 0.150 |
Why?
|
| Noninvasive Ventilation | 1 | 2017 | 24 | 0.150 |
Why?
|
| Early Diagnosis | 1 | 2018 | 125 | 0.150 |
Why?
|
| Troponin T | 1 | 2017 | 39 | 0.150 |
Why?
|
| Receptors, Adrenergic, beta | 3 | 2002 | 73 | 0.150 |
Why?
|
| Infusions, Intravenous | 4 | 2013 | 434 | 0.150 |
Why?
|
| Device Removal | 1 | 2019 | 167 | 0.150 |
Why?
|
| Prosthesis Fitting | 1 | 2017 | 16 | 0.150 |
Why?
|
| Online Systems | 2 | 1995 | 24 | 0.150 |
Why?
|
| Allografts | 1 | 2018 | 181 | 0.140 |
Why?
|
| Safety | 3 | 2009 | 149 | 0.140 |
Why?
|
| Statistics, Nonparametric | 4 | 2018 | 306 | 0.140 |
Why?
|
| Genetic Association Studies | 1 | 2019 | 294 | 0.140 |
Why?
|
| Family Practice | 1 | 1997 | 82 | 0.140 |
Why?
|
| Nose | 1 | 1997 | 94 | 0.140 |
Why?
|
| alpha-L-Fucosidase | 1 | 2016 | 3 | 0.140 |
Why?
|
| Radiation Dosage | 3 | 2016 | 225 | 0.140 |
Why?
|
| Pedigree | 1 | 2019 | 969 | 0.140 |
Why?
|
| Interleukin-18 | 1 | 2016 | 26 | 0.140 |
Why?
|
| Sleep Apnea, Obstructive | 2 | 2010 | 216 | 0.140 |
Why?
|
| Long QT Syndrome | 1 | 2016 | 36 | 0.140 |
Why?
|
| Atropine | 3 | 1997 | 60 | 0.140 |
Why?
|
| Catheter Ablation | 3 | 2009 | 252 | 0.140 |
Why?
|
| Breath Holding | 1 | 2016 | 22 | 0.140 |
Why?
|
| Equipment Safety | 1 | 2016 | 33 | 0.140 |
Why?
|
| Arrhythmias, Cardiac | 3 | 2021 | 197 | 0.140 |
Why?
|
| Blood Vessel Prosthesis | 1 | 1998 | 242 | 0.140 |
Why?
|
| Carcinoid Heart Disease | 1 | 1996 | 2 | 0.130 |
Why?
|
| Angiogenic Proteins | 1 | 2016 | 17 | 0.130 |
Why?
|
| Area Under Curve | 1 | 2016 | 337 | 0.130 |
Why?
|
| Hospitals, University | 3 | 2010 | 195 | 0.130 |
Why?
|
| Health Care Costs | 2 | 2013 | 235 | 0.130 |
Why?
|
| Radiation Protection | 1 | 2016 | 26 | 0.130 |
Why?
|
| Kaplan-Meier Estimate | 5 | 2017 | 859 | 0.130 |
Why?
|
| Electric Countershock | 2 | 2022 | 53 | 0.130 |
Why?
|
| Databases, Factual | 1 | 2019 | 850 | 0.130 |
Why?
|
| Parents | 1 | 2019 | 285 | 0.130 |
Why?
|
| Trastuzumab | 1 | 2016 | 71 | 0.130 |
Why?
|
| Lipoproteins, LDL | 1 | 2015 | 85 | 0.130 |
Why?
|
| Pulmonary Valve | 2 | 2015 | 34 | 0.130 |
Why?
|
| Education, Medical, Graduate | 1 | 2019 | 390 | 0.130 |
Why?
|
| Incidence | 3 | 2016 | 1592 | 0.130 |
Why?
|
| Hypotension | 1 | 1996 | 71 | 0.130 |
Why?
|
| Microvessels | 1 | 2015 | 69 | 0.130 |
Why?
|
| Lipoproteins, HDL | 1 | 2015 | 97 | 0.130 |
Why?
|
| Shock | 1 | 2015 | 44 | 0.130 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2016 | 109 | 0.130 |
Why?
|
| Delivery, Obstetric | 2 | 1993 | 118 | 0.130 |
Why?
|
| Compliance | 5 | 2005 | 21 | 0.130 |
Why?
|
| Age Distribution | 2 | 2009 | 200 | 0.130 |
Why?
|
| Administration, Oral | 3 | 2007 | 682 | 0.130 |
Why?
|
| Quantitative Trait Loci | 2 | 2016 | 607 | 0.130 |
Why?
|
| Macaca mulatta | 1 | 1997 | 466 | 0.120 |
Why?
|
| Japan | 4 | 2011 | 303 | 0.120 |
Why?
|
| Chronic Disease | 5 | 2018 | 948 | 0.120 |
Why?
|
| Captopril | 1 | 1994 | 20 | 0.120 |
Why?
|
| Mice, Inbred Strains | 4 | 2011 | 308 | 0.120 |
Why?
|
| Subclavian Artery | 1 | 1994 | 43 | 0.120 |
Why?
|
| Pilot Projects | 3 | 2016 | 865 | 0.120 |
Why?
|
| Stomach | 1 | 2015 | 111 | 0.120 |
Why?
|
| Microcirculation | 2 | 2006 | 104 | 0.120 |
Why?
|
| Cardiovascular Agents | 2 | 2009 | 54 | 0.120 |
Why?
|
| Vectorcardiography | 1 | 2013 | 8 | 0.120 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2013 | 22 | 0.110 |
Why?
|
| Logistic Models | 3 | 2006 | 1212 | 0.110 |
Why?
|
| Ureteroscopy | 1 | 2013 | 38 | 0.110 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2014 | 105 | 0.110 |
Why?
|
| Lithotripsy | 1 | 2013 | 42 | 0.110 |
Why?
|
| Respiratory Insufficiency | 1 | 2015 | 162 | 0.110 |
Why?
|
| Sample Size | 1 | 2013 | 128 | 0.110 |
Why?
|
| Tocolytic Agents | 1 | 1993 | 8 | 0.110 |
Why?
|
| Terbutaline | 1 | 1993 | 16 | 0.110 |
Why?
|
| Genetic Diseases, X-Linked | 1 | 2013 | 35 | 0.110 |
Why?
|
| Membrane Glycoproteins | 2 | 2013 | 432 | 0.110 |
Why?
|
| Ultrasonic Therapy | 1 | 2013 | 34 | 0.110 |
Why?
|
| Myocardial Reperfusion | 2 | 2004 | 28 | 0.110 |
Why?
|
| Thyroid Hormone Receptors beta | 2 | 2003 | 80 | 0.110 |
Why?
|
| Prolapse | 2 | 2003 | 10 | 0.110 |
Why?
|
| Graft Occlusion, Vascular | 2 | 2004 | 99 | 0.110 |
Why?
|
| Receptor, Adenosine A2B | 1 | 2012 | 1 | 0.110 |
Why?
|
| Research | 2 | 2013 | 252 | 0.110 |
Why?
|
| Fatal Outcome | 2 | 2004 | 299 | 0.110 |
Why?
|
| Respiration, Artificial | 1 | 2015 | 352 | 0.100 |
Why?
|
| Triage | 1 | 2013 | 111 | 0.100 |
Why?
|
| Rabbits | 6 | 2005 | 638 | 0.100 |
Why?
|
| N-Acetylgalactosaminyltransferases | 1 | 2012 | 12 | 0.100 |
Why?
|
| Inservice Training | 2 | 2021 | 38 | 0.100 |
Why?
|
| Aortic Aneurysm, Abdominal | 1 | 2013 | 120 | 0.100 |
Why?
|
| Circadian Rhythm | 2 | 1992 | 305 | 0.100 |
Why?
|
| Dogs | 7 | 2001 | 704 | 0.100 |
Why?
|
| Drug Combinations | 3 | 2023 | 202 | 0.100 |
Why?
|
| Valsartan | 2 | 2023 | 11 | 0.100 |
Why?
|
| Drug Hypersensitivity | 1 | 2012 | 37 | 0.100 |
Why?
|
| Vagus Nerve | 2 | 1991 | 49 | 0.100 |
Why?
|
| Cardiology Service, Hospital | 1 | 2011 | 4 | 0.100 |
Why?
|
| Anesthetics | 1 | 1992 | 53 | 0.100 |
Why?
|
| Cross-Over Studies | 3 | 2021 | 389 | 0.100 |
Why?
|
| Catheterization, Central Venous | 2 | 1991 | 115 | 0.100 |
Why?
|
| Receptors, Dopamine | 2 | 1988 | 37 | 0.100 |
Why?
|
| Pericarditis, Constrictive | 1 | 1991 | 5 | 0.100 |
Why?
|
| Emergency Service, Hospital | 2 | 2017 | 521 | 0.100 |
Why?
|
| Ventricular Septum | 1 | 2011 | 14 | 0.100 |
Why?
|
| Anesthesiology | 1 | 2014 | 161 | 0.100 |
Why?
|
| Plasma Substitutes | 1 | 1991 | 9 | 0.100 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 2011 | 66 | 0.100 |
Why?
|
| Magnetic Resonance Angiography | 3 | 2016 | 271 | 0.100 |
Why?
|
| Finite Element Analysis | 1 | 2011 | 78 | 0.090 |
Why?
|
| Atrioventricular Block | 1 | 2011 | 24 | 0.090 |
Why?
|
| Cardiac Tamponade | 1 | 1991 | 20 | 0.090 |
Why?
|
| Adrenergic beta-Antagonists | 4 | 2005 | 105 | 0.090 |
Why?
|
| Referral and Consultation | 2 | 2008 | 341 | 0.090 |
Why?
|
| Quality of Life | 3 | 2021 | 1662 | 0.090 |
Why?
|
| Calcium | 3 | 1996 | 1172 | 0.090 |
Why?
|
| Sodium Channels | 1 | 2011 | 129 | 0.090 |
Why?
|
| Watchful Waiting | 1 | 2011 | 63 | 0.090 |
Why?
|
| Particulate Matter | 1 | 2011 | 102 | 0.090 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2013 | 181 | 0.090 |
Why?
|
| Physical Exertion | 1 | 1990 | 38 | 0.090 |
Why?
|
| Aortography | 3 | 2010 | 65 | 0.090 |
Why?
|
| Kidney Calculi | 1 | 2013 | 341 | 0.090 |
Why?
|
| Health Status Disparities | 1 | 2012 | 187 | 0.090 |
Why?
|
| Torsion, Mechanical | 1 | 2010 | 6 | 0.090 |
Why?
|
| Air Pollutants | 1 | 2011 | 92 | 0.090 |
Why?
|
| Natriuretic Peptide, Brain | 2 | 2012 | 51 | 0.090 |
Why?
|
| Acute Disease | 3 | 2015 | 841 | 0.090 |
Why?
|
| Cardiomegaly | 2 | 2006 | 120 | 0.090 |
Why?
|
| Neoplasm Proteins | 1 | 2013 | 540 | 0.090 |
Why?
|
| Ultrasonography, Doppler, Color | 2 | 2018 | 38 | 0.090 |
Why?
|
| Organizational Objectives | 1 | 2009 | 24 | 0.090 |
Why?
|
| Syndrome | 2 | 2011 | 449 | 0.090 |
Why?
|
| Anthropometry | 2 | 2013 | 75 | 0.090 |
Why?
|
| Blood Circulation | 2 | 2004 | 30 | 0.090 |
Why?
|
| Amyloid | 1 | 2010 | 94 | 0.090 |
Why?
|
| KATP Channels | 1 | 2009 | 19 | 0.090 |
Why?
|
| Respiration | 1 | 1991 | 267 | 0.090 |
Why?
|
| Receptors, Drug | 1 | 2009 | 54 | 0.080 |
Why?
|
| Nitroprusside | 5 | 1998 | 32 | 0.080 |
Why?
|
| Radiography | 2 | 2009 | 809 | 0.080 |
Why?
|
| Propanolamines | 3 | 1998 | 18 | 0.080 |
Why?
|
| Muscular Diseases | 1 | 2009 | 64 | 0.080 |
Why?
|
| Fluoroscopy | 3 | 2019 | 122 | 0.080 |
Why?
|
| Health Status Indicators | 1 | 2009 | 103 | 0.080 |
Why?
|
| Technology Assessment, Biomedical | 2 | 2013 | 27 | 0.080 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2009 | 142 | 0.080 |
Why?
|
| Reference Standards | 3 | 2018 | 144 | 0.080 |
Why?
|
| Carotid Body | 1 | 2011 | 234 | 0.080 |
Why?
|
| Receptors, Adrenergic | 1 | 1988 | 15 | 0.080 |
Why?
|
| Longitudinal Studies | 2 | 2023 | 1067 | 0.080 |
Why?
|
| Potassium Channels, Inwardly Rectifying | 1 | 2009 | 121 | 0.080 |
Why?
|
| Internet | 1 | 2011 | 318 | 0.080 |
Why?
|
| Patient Discharge | 1 | 2011 | 320 | 0.080 |
Why?
|
| Double-Blind Method | 4 | 1997 | 1714 | 0.080 |
Why?
|
| Community Health Centers | 1 | 2009 | 115 | 0.080 |
Why?
|
| Kidney | 1 | 2013 | 1145 | 0.080 |
Why?
|
| Peptide Fragments | 2 | 2012 | 463 | 0.080 |
Why?
|
| Diabetes Complications | 1 | 2009 | 170 | 0.080 |
Why?
|
| Ambulatory Care | 1 | 2009 | 187 | 0.080 |
Why?
|
| Washington | 1 | 2007 | 49 | 0.080 |
Why?
|
| Surveys and Questionnaires | 1 | 2016 | 2612 | 0.080 |
Why?
|
| False Positive Reactions | 3 | 2006 | 222 | 0.080 |
Why?
|
| Benzenesulfonates | 1 | 2008 | 66 | 0.070 |
Why?
|
| Pregnancy Trimester, Third | 2 | 2018 | 70 | 0.070 |
Why?
|
| Clinical Decision-Making | 2 | 2020 | 280 | 0.070 |
Why?
|
| Pulmonary Veins | 1 | 2008 | 93 | 0.070 |
Why?
|
| Motor Activity | 1 | 2010 | 327 | 0.070 |
Why?
|
| Reoperation | 2 | 2012 | 598 | 0.070 |
Why?
|
| Cardiopulmonary Bypass | 2 | 2012 | 157 | 0.070 |
Why?
|
| Critical Care | 2 | 2002 | 380 | 0.070 |
Why?
|
| Perinatology | 1 | 2006 | 14 | 0.070 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2016 | 2335 | 0.070 |
Why?
|
| Miniaturization | 2 | 2015 | 14 | 0.070 |
Why?
|
| Intensive Care Units | 2 | 2015 | 395 | 0.070 |
Why?
|
| Gated Blood-Pool Imaging | 1 | 2006 | 8 | 0.070 |
Why?
|
| Survival Analysis | 3 | 2018 | 1533 | 0.070 |
Why?
|
| Sex Distribution | 2 | 2011 | 171 | 0.070 |
Why?
|
| Biomedical Research | 1 | 2011 | 398 | 0.070 |
Why?
|
| Hemoglobins | 2 | 2017 | 192 | 0.070 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2006 | 51 | 0.070 |
Why?
|
| Thoracic Wall | 1 | 2006 | 25 | 0.070 |
Why?
|
| Muscle, Skeletal | 1 | 2009 | 466 | 0.070 |
Why?
|
| Body Weight | 3 | 2003 | 452 | 0.070 |
Why?
|
| Computer Graphics | 2 | 2014 | 100 | 0.070 |
Why?
|
| Angiotensin II | 1 | 2006 | 93 | 0.070 |
Why?
|
| Pyridines | 1 | 2008 | 315 | 0.070 |
Why?
|
| Calcium Channel Blockers | 3 | 2004 | 121 | 0.070 |
Why?
|
| Radiographic Image Enhancement | 1 | 2008 | 463 | 0.070 |
Why?
|
| Ultrasonography, Prenatal | 1 | 2006 | 152 | 0.060 |
Why?
|
| Constriction, Pathologic | 2 | 2004 | 217 | 0.060 |
Why?
|
| Pulsatile Flow | 2 | 2013 | 50 | 0.060 |
Why?
|
| Information Storage and Retrieval | 1 | 2006 | 121 | 0.060 |
Why?
|
| Compact Disks | 1 | 2005 | 3 | 0.060 |
Why?
|
| Gene Expression Regulation | 4 | 2016 | 1975 | 0.060 |
Why?
|
| Phantoms, Imaging | 3 | 2016 | 448 | 0.060 |
Why?
|
| Sex Characteristics | 2 | 2001 | 324 | 0.060 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 1990 | 559 | 0.060 |
Why?
|
| Genetic Markers | 2 | 2019 | 478 | 0.060 |
Why?
|
| Medical Illustration | 1 | 2004 | 16 | 0.060 |
Why?
|
| Registries | 3 | 2016 | 778 | 0.060 |
Why?
|
| Cerebrovascular Disorders | 1 | 2005 | 143 | 0.060 |
Why?
|
| Vascular Diseases | 1 | 2005 | 118 | 0.060 |
Why?
|
| Hypertrophy, Right Ventricular | 2 | 2008 | 33 | 0.060 |
Why?
|
| User-Computer Interface | 1 | 2006 | 187 | 0.060 |
Why?
|
| Postoperative Care | 2 | 2018 | 229 | 0.060 |
Why?
|
| Vascular Surgical Procedures | 1 | 2005 | 149 | 0.060 |
Why?
|
| Nifedipine | 2 | 1995 | 25 | 0.060 |
Why?
|
| Coronary Vasospasm | 1 | 2004 | 8 | 0.060 |
Why?
|
| Mice, Mutant Strains | 3 | 2011 | 231 | 0.060 |
Why?
|
| Pancreatitis, Acute Necrotizing | 1 | 2004 | 16 | 0.060 |
Why?
|
| Injections, Intravenous | 1 | 2004 | 240 | 0.060 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2016 | 374 | 0.060 |
Why?
|
| Muscle, Smooth, Vascular | 2 | 2004 | 241 | 0.060 |
Why?
|
| Thallium | 1 | 2003 | 8 | 0.060 |
Why?
|
| Organotechnetium Compounds | 1 | 2003 | 11 | 0.060 |
Why?
|
| Information Dissemination | 1 | 2005 | 114 | 0.060 |
Why?
|
| Hospitals, General | 1 | 2003 | 12 | 0.060 |
Why?
|
| Emergency Medical Services | 2 | 2018 | 238 | 0.060 |
Why?
|
| Polysomnography | 2 | 2017 | 151 | 0.060 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2008 | 604 | 0.060 |
Why?
|
| Prealbumin | 1 | 2023 | 34 | 0.060 |
Why?
|
| Organophosphorus Compounds | 1 | 2003 | 55 | 0.050 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2019 | 2399 | 0.050 |
Why?
|
| Angioplasty, Balloon | 1 | 2003 | 96 | 0.050 |
Why?
|
| Computing Methodologies | 1 | 2002 | 9 | 0.050 |
Why?
|
| Infant, Newborn | 2 | 2010 | 2476 | 0.050 |
Why?
|
| Brazil | 1 | 2023 | 71 | 0.050 |
Why?
|
| Educational Measurement | 1 | 2005 | 231 | 0.050 |
Why?
|
| Thyroid Hormone Resistance Syndrome | 1 | 2003 | 117 | 0.050 |
Why?
|
| Marketing of Health Services | 1 | 2002 | 15 | 0.050 |
Why?
|
| Methicillin Resistance | 1 | 2003 | 32 | 0.050 |
Why?
|
| Minimally Invasive Surgical Procedures | 2 | 2016 | 251 | 0.050 |
Why?
|
| Adenosine | 3 | 2016 | 237 | 0.050 |
Why?
|
| Spain | 2 | 2017 | 32 | 0.050 |
Why?
|
| Palliative Care | 1 | 2004 | 263 | 0.050 |
Why?
|
| Thyroid Function Tests | 1 | 2002 | 120 | 0.050 |
Why?
|
| Renal Dialysis | 3 | 1991 | 335 | 0.050 |
Why?
|
| Cost-Benefit Analysis | 2 | 2013 | 461 | 0.050 |
Why?
|
| Genomics | 1 | 2008 | 761 | 0.050 |
Why?
|
| Myocardial Reperfusion Injury | 1 | 2002 | 58 | 0.050 |
Why?
|
| Breast Neoplasms | 1 | 2016 | 3000 | 0.050 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2002 | 108 | 0.050 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2005 | 376 | 0.050 |
Why?
|
| Mice, Knockout | 2 | 2006 | 1990 | 0.050 |
Why?
|
| Laboratories | 1 | 2021 | 44 | 0.050 |
Why?
|
| Goals | 1 | 2022 | 67 | 0.050 |
Why?
|
| Preoperative Period | 2 | 2012 | 94 | 0.050 |
Why?
|
| Gestational Age | 2 | 2016 | 323 | 0.050 |
Why?
|
| Physical Conditioning, Animal | 1 | 2000 | 19 | 0.050 |
Why?
|
| Clinical Trials as Topic | 1 | 2006 | 1149 | 0.050 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2003 | 226 | 0.040 |
Why?
|
| Single-Blind Method | 2 | 2013 | 150 | 0.040 |
Why?
|
| Staphylococcal Infections | 1 | 2003 | 269 | 0.040 |
Why?
|
| Isoproterenol | 2 | 1997 | 62 | 0.040 |
Why?
|
| Neprilysin | 1 | 2019 | 41 | 0.040 |
Why?
|
| Baltimore | 2 | 2011 | 40 | 0.040 |
Why?
|
| Students, Medical | 1 | 2005 | 418 | 0.040 |
Why?
|
| Heart Conduction System | 2 | 2010 | 112 | 0.040 |
Why?
|
| Vocabulary, Controlled | 1 | 2019 | 13 | 0.040 |
Why?
|
| Biphenyl Compounds | 1 | 2019 | 59 | 0.040 |
Why?
|
| Thorax | 1 | 1999 | 77 | 0.040 |
Why?
|
| Certification | 1 | 2019 | 61 | 0.040 |
Why?
|
| Body Mass Index | 2 | 2017 | 771 | 0.040 |
Why?
|
| Hepatic Veins | 1 | 1999 | 26 | 0.040 |
Why?
|
| Hospital Mortality | 1 | 2021 | 386 | 0.040 |
Why?
|
| Genotype | 2 | 2016 | 1848 | 0.040 |
Why?
|
| Fourier Analysis | 2 | 1996 | 126 | 0.040 |
Why?
|
| Obesity | 1 | 2005 | 966 | 0.040 |
Why?
|
| Anesthetics, Dissociative | 1 | 1997 | 5 | 0.040 |
Why?
|
| Methoxamine | 1 | 1997 | 3 | 0.040 |
Why?
|
| Cost of Illness | 1 | 2018 | 147 | 0.040 |
Why?
|
| Muscle Contraction | 1 | 2019 | 284 | 0.040 |
Why?
|
| Health Services Research | 1 | 1998 | 137 | 0.040 |
Why?
|
| Health Resources | 1 | 1998 | 81 | 0.040 |
Why?
|
| Pressure | 1 | 1998 | 165 | 0.040 |
Why?
|
| Adrenergic alpha-Agonists | 1 | 1997 | 33 | 0.040 |
Why?
|
| Ketamine | 1 | 1997 | 25 | 0.040 |
Why?
|
| Spirometry | 1 | 2017 | 68 | 0.040 |
Why?
|
| Mouth | 1 | 1997 | 48 | 0.040 |
Why?
|
| Transplantation, Autologous | 1 | 2018 | 343 | 0.040 |
Why?
|
| Surface Properties | 1 | 1997 | 131 | 0.040 |
Why?
|
| Body Size | 1 | 2017 | 91 | 0.040 |
Why?
|
| Acute Chest Syndrome | 1 | 2017 | 16 | 0.040 |
Why?
|
| Conscious Sedation | 1 | 1997 | 69 | 0.040 |
Why?
|
| Wakefulness | 1 | 1997 | 135 | 0.040 |
Why?
|
| Leukocyte Count | 1 | 2017 | 223 | 0.040 |
Why?
|
| Life Style | 1 | 2017 | 172 | 0.040 |
Why?
|
| Muscarinic Antagonists | 1 | 1997 | 58 | 0.040 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2016 | 71 | 0.030 |
Why?
|
| Aspartate Aminotransferases | 1 | 2016 | 74 | 0.030 |
Why?
|
| Health Care Surveys | 1 | 1997 | 280 | 0.030 |
Why?
|
| Hemolysis | 1 | 2016 | 64 | 0.030 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2016 | 51 | 0.030 |
Why?
|
| Hydroxyurea | 1 | 2016 | 239 | 0.030 |
Why?
|
| Activities of Daily Living | 1 | 1997 | 207 | 0.030 |
Why?
|
| Technetium Tc 99m Sestamibi | 1 | 1996 | 15 | 0.030 |
Why?
|
| Infusions, Parenteral | 2 | 2005 | 51 | 0.030 |
Why?
|
| Carotid Intima-Media Thickness | 1 | 2016 | 38 | 0.030 |
Why?
|
| Central Venous Pressure | 1 | 2015 | 26 | 0.030 |
Why?
|
| Equipment Failure | 1 | 2016 | 121 | 0.030 |
Why?
|
| Models, Anatomic | 1 | 2016 | 91 | 0.030 |
Why?
|
| Radiation, Ionizing | 1 | 2016 | 121 | 0.030 |
Why?
|
| Lung | 2 | 2015 | 1258 | 0.030 |
Why?
|
| Dyspnea | 1 | 1996 | 75 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2002 | 3209 | 0.030 |
Why?
|
| Ramipril | 1 | 1995 | 2 | 0.030 |
Why?
|
| Alleles | 1 | 2019 | 1135 | 0.030 |
Why?
|
| Myocarditis | 1 | 1995 | 51 | 0.030 |
Why?
|
| Atenolol | 1 | 1995 | 26 | 0.030 |
Why?
|
| Perfusion | 2 | 2013 | 235 | 0.030 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 1997 | 333 | 0.030 |
Why?
|
| Obesity, Morbid | 1 | 2017 | 233 | 0.030 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 1994 | 31 | 0.030 |
Why?
|
| Drug Tolerance | 1 | 1994 | 64 | 0.030 |
Why?
|
| Calibration | 1 | 1994 | 104 | 0.030 |
Why?
|
| Resuscitation | 1 | 1995 | 109 | 0.030 |
Why?
|
| Pregnancy Outcome | 1 | 2016 | 253 | 0.030 |
Why?
|
| Gene Expression Profiling | 2 | 2012 | 1429 | 0.030 |
Why?
|
| Shock, Septic | 1 | 1995 | 104 | 0.030 |
Why?
|
| Kidney Failure, Chronic | 3 | 1993 | 413 | 0.030 |
Why?
|
| Torque | 1 | 2013 | 10 | 0.030 |
Why?
|
| Transplantation, Homologous | 1 | 1996 | 995 | 0.030 |
Why?
|
| Hepatitis A Virus Cellular Receptor 1 | 1 | 2013 | 17 | 0.030 |
Why?
|
| London | 1 | 2013 | 16 | 0.030 |
Why?
|
| Myocardial Revascularization | 1 | 2013 | 30 | 0.030 |
Why?
|
| Internship and Residency | 1 | 2003 | 1041 | 0.030 |
Why?
|
| Receptors, Virus | 1 | 2013 | 75 | 0.030 |
Why?
|
| Signal-To-Noise Ratio | 1 | 2014 | 103 | 0.030 |
Why?
|
| Familial Primary Pulmonary Hypertension | 1 | 2013 | 60 | 0.030 |
Why?
|
| Nephrolithiasis | 1 | 2013 | 23 | 0.030 |
Why?
|
| Erythropoietin | 1 | 1993 | 88 | 0.030 |
Why?
|
| Models, Genetic | 1 | 2019 | 944 | 0.030 |
Why?
|
| Cost Savings | 1 | 2013 | 69 | 0.030 |
Why?
|
| Models, Economic | 1 | 2013 | 62 | 0.030 |
Why?
|
| Nicardipine | 1 | 1993 | 7 | 0.030 |
Why?
|
| Bioengineering | 1 | 2013 | 13 | 0.030 |
Why?
|
| Purinergic P1 Receptor Antagonists | 1 | 2012 | 6 | 0.030 |
Why?
|
| Benchmarking | 1 | 2013 | 79 | 0.030 |
Why?
|
| Aminophylline | 1 | 2012 | 14 | 0.030 |
Why?
|
| Pulmonary Valve Stenosis | 1 | 1993 | 18 | 0.030 |
Why?
|
| Hospitalization | 1 | 1998 | 876 | 0.030 |
Why?
|
| Chloralose | 1 | 1992 | 6 | 0.030 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 1997 | 531 | 0.030 |
Why?
|
| Anemia | 1 | 1993 | 129 | 0.030 |
Why?
|
| Pentobarbital | 1 | 1992 | 20 | 0.030 |
Why?
|
| Adenosine A2 Receptor Antagonists | 1 | 2012 | 13 | 0.030 |
Why?
|
| Support Vector Machine | 1 | 2012 | 25 | 0.030 |
Why?
|
| Congresses as Topic | 1 | 2013 | 112 | 0.030 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2016 | 481 | 0.030 |
Why?
|
| Microarray Analysis | 1 | 2012 | 96 | 0.030 |
Why?
|
| Interprofessional Relations | 1 | 2013 | 122 | 0.030 |
Why?
|
| Transcriptome | 1 | 2017 | 628 | 0.030 |
Why?
|
| Fentanyl | 1 | 1992 | 67 | 0.030 |
Why?
|
| Percutaneous Coronary Intervention | 1 | 2013 | 64 | 0.030 |
Why?
|
| Blood Pressure Monitors | 1 | 1991 | 8 | 0.030 |
Why?
|
| NAV1.5 Voltage-Gated Sodium Channel | 1 | 2011 | 32 | 0.020 |
Why?
|
| Bradycardia | 1 | 2011 | 40 | 0.020 |
Why?
|
| Safety Management | 1 | 2012 | 56 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2013 | 783 | 0.020 |
Why?
|
| Polytetrafluoroethylene | 1 | 2011 | 74 | 0.020 |
Why?
|
| Electromagnetic Phenomena | 1 | 1991 | 18 | 0.020 |
Why?
|
| Morphine | 1 | 1992 | 130 | 0.020 |
Why?
|
| Rheology | 1 | 1991 | 39 | 0.020 |
Why?
|
| Isotonic Solutions | 1 | 1991 | 17 | 0.020 |
Why?
|
| Labor, Obstetric | 1 | 1991 | 46 | 0.020 |
Why?
|
| Diagnostic Test Approval | 1 | 2010 | 2 | 0.020 |
Why?
|
| Intubation, Intratracheal | 1 | 1992 | 148 | 0.020 |
Why?
|
| Jugular Veins | 1 | 1991 | 74 | 0.020 |
Why?
|
| Prostheses and Implants | 1 | 2011 | 124 | 0.020 |
Why?
|
| Research Support as Topic | 1 | 2011 | 85 | 0.020 |
Why?
|
| Fundus Oculi | 1 | 1990 | 33 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2012 | 1940 | 0.020 |
Why?
|
| Parathyroid Hormone | 1 | 1991 | 216 | 0.020 |
Why?
|
| Urban Population | 1 | 1991 | 224 | 0.020 |
Why?
|
| Quality Control | 1 | 2010 | 117 | 0.020 |
Why?
|
| Parasympathetic Nervous System | 1 | 1990 | 36 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2012 | 894 | 0.020 |
Why?
|
| Lidocaine | 1 | 1990 | 65 | 0.020 |
Why?
|
| Angiography | 2 | 2007 | 208 | 0.020 |
Why?
|
| Autonomic Nervous System | 1 | 1990 | 65 | 0.020 |
Why?
|
| Sarcolemma | 1 | 2009 | 31 | 0.020 |
Why?
|
| Diatrizoate Meglumine | 2 | 2005 | 19 | 0.020 |
Why?
|
| Critical Illness | 1 | 2012 | 306 | 0.020 |
Why?
|
| Sulfonylurea Receptors | 1 | 2009 | 50 | 0.020 |
Why?
|
| Angioscopy | 1 | 2009 | 3 | 0.020 |
Why?
|
| Foramen Ovale, Patent | 1 | 2009 | 18 | 0.020 |
Why?
|
| Data Collection | 1 | 2011 | 375 | 0.020 |
Why?
|
| Postoperative Period | 1 | 2010 | 301 | 0.020 |
Why?
|
| Communication | 1 | 2013 | 457 | 0.020 |
Why?
|
| Recurrence | 1 | 2012 | 1140 | 0.020 |
Why?
|
| Fiber Optic Technology | 1 | 2009 | 35 | 0.020 |
Why?
|
| Necrosis | 1 | 2009 | 209 | 0.020 |
Why?
|
| Domperidone | 1 | 1988 | 8 | 0.020 |
Why?
|
| Queensland | 1 | 2008 | 5 | 0.020 |
Why?
|
| Yohimbine | 1 | 1988 | 7 | 0.020 |
Why?
|
| Prazosin | 1 | 1988 | 10 | 0.020 |
Why?
|
| Sus scrofa | 1 | 2008 | 50 | 0.020 |
Why?
|
| Rats, Inbred Dahl | 1 | 2008 | 8 | 0.020 |
Why?
|
| Complement C1q | 1 | 2008 | 11 | 0.020 |
Why?
|
| Cations, Divalent | 1 | 1988 | 39 | 0.020 |
Why?
|
| Regeneration | 1 | 2009 | 150 | 0.020 |
Why?
|
| Transforming Growth Factor beta3 | 1 | 2008 | 16 | 0.020 |
Why?
|
| Retina | 1 | 1990 | 219 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2008 | 85 | 0.020 |
Why?
|
| Niacinamide | 1 | 2008 | 116 | 0.020 |
Why?
|
| Weight Loss | 1 | 2009 | 225 | 0.020 |
Why?
|
| Embolectomy | 1 | 2007 | 6 | 0.020 |
Why?
|
| Phenylurea Compounds | 1 | 2008 | 114 | 0.020 |
Why?
|
| Probability | 1 | 2008 | 353 | 0.020 |
Why?
|
| Homeostasis | 1 | 2009 | 413 | 0.020 |
Why?
|
| Apoptosis | 2 | 2008 | 1716 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2008 | 226 | 0.020 |
Why?
|
| Electrophysiology | 1 | 2007 | 403 | 0.020 |
Why?
|
| Mass Screening | 1 | 2011 | 636 | 0.020 |
Why?
|
| Cooperative Behavior | 1 | 2008 | 179 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2008 | 698 | 0.020 |
Why?
|
| Endomyocardial Fibrosis | 1 | 2006 | 6 | 0.020 |
Why?
|
| Muscle Cells | 1 | 2006 | 18 | 0.020 |
Why?
|
| Poly (ADP-Ribose) Polymerase-1 | 1 | 2006 | 25 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2008 | 794 | 0.020 |
Why?
|
| NAD | 1 | 2006 | 71 | 0.020 |
Why?
|
| Sirtuin 1 | 1 | 2006 | 32 | 0.020 |
Why?
|
| Sirtuins | 1 | 2006 | 46 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2008 | 887 | 0.020 |
Why?
|
| Ventriculography, First-Pass | 1 | 2005 | 2 | 0.020 |
Why?
|
| Intermittent Claudication | 1 | 2005 | 20 | 0.020 |
Why?
|
| Oxides | 1 | 2005 | 43 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2008 | 695 | 0.020 |
Why?
|
| Ferric Compounds | 1 | 2005 | 38 | 0.020 |
Why?
|
| Patient Care Team | 1 | 2008 | 283 | 0.020 |
Why?
|
| Aortic Coarctation | 1 | 2005 | 36 | 0.020 |
Why?
|
| Blood Glucose | 1 | 2009 | 836 | 0.020 |
Why?
|
| Aneurysm | 1 | 2005 | 60 | 0.020 |
Why?
|
| Genetic Variation | 1 | 1992 | 1371 | 0.020 |
Why?
|
| Iron | 1 | 2005 | 168 | 0.020 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2006 | 217 | 0.020 |
Why?
|
| Creatine Kinase, MB Form | 1 | 2004 | 7 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2016 | 2411 | 0.010 |
Why?
|
| Extremities | 1 | 2005 | 169 | 0.010 |
Why?
|
| Creatine Kinase | 1 | 2004 | 52 | 0.010 |
Why?
|
| Sarcoglycans | 1 | 2004 | 14 | 0.010 |
Why?
|
| Verapamil | 1 | 2004 | 34 | 0.010 |
Why?
|
| Propylthiouracil | 1 | 2003 | 27 | 0.010 |
Why?
|
| Cardiovascular Abnormalities | 1 | 2003 | 7 | 0.010 |
Why?
|
| Immunoblotting | 1 | 2004 | 273 | 0.010 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2004 | 323 | 0.010 |
Why?
|
| Isoenzymes | 1 | 2004 | 274 | 0.010 |
Why?
|
| Oxidative Stress | 1 | 2006 | 458 | 0.010 |
Why?
|
| Patient Admission | 1 | 2003 | 114 | 0.010 |
Why?
|
| Cytoskeletal Proteins | 1 | 2004 | 228 | 0.010 |
Why?
|
| beta-Adrenergic Receptor Kinases | 1 | 2002 | 11 | 0.010 |
Why?
|
| Atrial Natriuretic Factor | 1 | 2002 | 39 | 0.010 |
Why?
|
| Forms and Records Control | 1 | 2002 | 16 | 0.010 |
Why?
|
| Length of Stay | 1 | 2005 | 732 | 0.010 |
Why?
|
| Triiodothyronine | 1 | 2003 | 344 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2008 | 1650 | 0.010 |
Why?
|
| Diltiazem | 1 | 2001 | 7 | 0.010 |
Why?
|
| Muscle Tonus | 1 | 2001 | 19 | 0.010 |
Why?
|
| Muscle Relaxation | 1 | 2001 | 18 | 0.010 |
Why?
|
| Rats | 1 | 2008 | 4040 | 0.010 |
Why?
|
| Stimulation, Chemical | 2 | 1993 | 63 | 0.010 |
Why?
|
| Germ-Line Mutation | 1 | 2003 | 344 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2006 | 2880 | 0.010 |
Why?
|
| Gene Expression | 1 | 2003 | 1310 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2000 | 921 | 0.010 |
Why?
|
| Myosin Heavy Chains | 1 | 1998 | 91 | 0.010 |
Why?
|
| Mutation | 1 | 2009 | 4132 | 0.010 |
Why?
|
| Spectrophotometry, Ultraviolet | 1 | 1996 | 44 | 0.010 |
Why?
|
| Physicians | 1 | 2004 | 689 | 0.010 |
Why?
|
| Endotoxins | 1 | 1995 | 36 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2006 | 3373 | 0.010 |
Why?
|
| Vasoconstriction | 1 | 1995 | 92 | 0.010 |
Why?
|
| Models, Biological | 1 | 2001 | 1763 | 0.010 |
Why?
|
| Reflex | 1 | 1993 | 80 | 0.010 |
Why?
|
| Sympathetic Nervous System | 1 | 1993 | 94 | 0.010 |
Why?
|
| South Africa | 1 | 1992 | 60 | 0.010 |
Why?
|
| Creatine | 1 | 1992 | 25 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 1993 | 1012 | 0.010 |
Why?
|
| Haplorhini | 1 | 1991 | 81 | 0.010 |
Why?
|
| Parathyroidectomy | 1 | 1991 | 77 | 0.010 |
Why?
|
| Potassium | 1 | 1992 | 253 | 0.010 |
Why?
|
| Sodium | 1 | 1992 | 331 | 0.010 |
Why?
|
| Amrinone | 1 | 1989 | 2 | 0.010 |
Why?
|
| Hemodialysis Solutions | 1 | 1989 | 2 | 0.010 |
Why?
|
| Electric Stimulation | 1 | 1990 | 354 | 0.010 |
Why?
|
| Diatrizoate | 1 | 1988 | 11 | 0.000 |
Why?
|
| Oxygen Consumption | 1 | 1988 | 243 | 0.000 |
Why?
|